MedPath

Research on the Brain Death Determination in China

Completed
Conditions
Brain Death
Evoked Potential
Quality Control
Electroencephalogram
TCD
Registration Number
NCT05903443
Lead Sponsor
Xuanwu Hospital, Beijing
Brief Summary

Purpose China has a population of 1.4 billion and an enormous medical expenditure burden, and Chinese traditional culture has a long history. It takes time to recognize and accept the concept of brain death (BD) as death. Promoting brain death determination (BDD) and rationally allocating medical resources have become major national policy issues. To identify the safest and most reliable ancillary tests needed if the clinical examination is incomplete.

Method The technical group of the Brain Injury Evaluation Quality Control Center of the National Health Commission retrieved coma cases registered from 2013 to 2019. According to clinical criteria for Brain Death Determination (BDD), the patients were divided into two groups: a brain-death (BD) group and a non-BD group. The BD group was divided into a complete brain death with no doubt group (BD1 group) and an incomplete brain death with doubt group (BD2 group). Depending on the site of the brain injury, the accuracy of BDD was evaluated using the independent ancillary test or combined ancillary tests. Data from the BQCC/NHC database and yearbook were obtained, and data analysis and status comparison were conducted on six practical activities: organizational system construction, standard and specification formulation, case quality control, professional skills training, scientific research publicity and education, and international communication.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1974
Inclusion Criteria
  • All cases met the clinical criteria for BD, involving deep coma (Glasgow Coma Scale (GCS)=2T), the absence of brainstem reflexes (pupillary light reflex, corneal reflex, oculocephalogyric reflex, oculovestibular reflex, and cough reflex), and spontaneous respiration. Ancillary tests were completed for all patients.
Exclusion Criteria
  • Does not meet BD clinical evaluation criteria. Ancillary tests were not implemented.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sensitivity1 month

The sensitivity of BDD was evaluated using the independent ancillary test and combined ancillary tests

specificity1 month

The specificity of BDD was evaluated using the independent ancillary test and combined ancillary tests

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Xuanwu Hospital

🇨🇳

Beijing, Beijing, China

Xuanwu Hospital
🇨🇳Beijing, Beijing, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.